SNF

Amgen’s share price has run up in anticipation of positive results from its key pipeline product Repatha. Now that the results are out, doubt has crept in concerning the overall viability of the product. Let’s examine. By Alexander J. Poulos Amgen (AMGN) remains a biotech bellwether, as the company continues to profit from its legacy product line. The established product line enhances the equity’s appeal as the cash flow generated is returned to shareholders in the form of a generous dividend. The company currently yields ~2.8%. For many conservative, income-seeking investors Amgen remains a top consideration in what many perceive as a “risky industry.” Amgen’s Dividend Cushion ratio >> That said, what many hopeful investors may not realize is that … Read more